Royal Fund Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12.8M | Buy |
50,828
+3,590
| +8% | +$772K | 1.07% | 20 |
|
|
2026
Q1 | $10.3M | Buy |
47,238
+3,097
| +7% | +$687K | 0.98% | 24 |
|
|
2025
Q4 | $10.1M | Buy |
44,141
+10,064
| +30% | +$2.29M | 0.92% | 31 |
|
|
2025
Q3 | $7.9M | Sell |
34,077
-12,087
| -26% | -$2.46M | 0.94% | 28 |
|
|
2025
Q2 | $8.57M | Buy |
46,164
+3,165
| +7% | +$588K | 0.85% | 28 |
|
|
2025
Q1 | $9.11M | Sell |
42,999
-1,540
| -3% | -$299K | 1.01% | 15 |
|
|
2024
Q4 | $8M | Sell |
44,539
-4,418
| -9% | -$812K | 0.75% | 32 |
|
|
2024
Q3 | $9.76M | Buy |
48,957
+2,292
| +5% | +$428K | 0.58% | 40 |
|
|
2024
Q2 | $8.09M | Sell |
46,665
-638
| -1% | -$106K | 0.65% | 21 |
|
|
2024
Q1 | $8.62M | Sell |
47,303
-603
| -1% | -$104K | 0.85% | 25 |
|
|
2023
Q4 | $7.43M | Sell |
47,906
-199
| -0.4% | -$29K | 0.82% | 29 |
|
|
2023
Q3 | $7.17M | Sell |
48,105
-1,326
| -3% | -$195K | 0.97% | 27 |
|
|
2023
Q2 | $6.66M | Buy |
49,431
+4,005
| +9% | +$587K | 0.83% | 31 |
|
|
2023
Q1 | $7.24M | Buy |
45,426
+2,967
| +7% | +$454K | 1.04% | 21 |
|
|
2022
Q4 | $6.86M | Buy |
42,459
+3,327
| +9% | +$510K | 1.09% | 23 |
|
|
2022
Q3 | $5.25M | Sell |
39,132
-2,074
| -5% | -$298K | 0.95% | 30 |
|
|
2022
Q2 | $6.31M | Buy |
41,206
+1,894
| +5% | +$289K | 1.05% | 28 |
|
|
2022
Q1 | $6.37M | Sell |
39,312
-981
| -2% | -$143K | 0.92% | 31 |
|
|
2021
Q4 | $5.46M | Buy |
40,293
+497
| +1% | +$58.7K | 0.78% | 39 |
|
|
2021
Q3 | $4.29M | Buy |
39,796
+728
| +2% | +$83.2K | 0.63% | 59 |
|
|
2021
Q2 | $4.4M | Sell |
39,068
-839
| -2% | -$94.5K | 0.73% | 52 |
|
|
2021
Q1 | $4.32M | Buy |
39,907
+1,629
| +4% | +$174K | 0.79% | 50 |
|
|
2020
Q4 | $4.1M | Sell |
38,278
-2,407
| -6% | -$231K | 0.87% | 44 |
|
|
2020
Q3 | $3.56M | Sell |
40,685
-4,516
| -10% | -$425K | 0.91% | 46 |
|
|
2020
Q2 | $4.44M | Buy |
45,201
+8,795
| +24% | +$774K | 1.56% | 12 |
|
|
2020
Q1 | $2.77M | Sell |
36,406
-57,288
| -61% | -$4.88M | 1.13% | 32 |
|
|
2019
Q4 | $8.29M | Sell |
93,694
-10,079
| -10% | -$837K | 2.11% | 10 |
|
|
2019
Q3 | $7.86M | Buy |
103,773
+28,789
| +38% | +$1.97M | 2.19% | 11 |
|
|
2019
Q2 | $5.45M | Sell |
74,984
-5,562
| -7% | -$437K | 1.62% | 21 |
|
|
2019
Q1 | $6.49M | Sell |
80,546
-1,702
| -2% | -$139K | 2.07% | 16 |
|
|
2018
Q4 | $7.58M | Sell |
82,248
-67,291
| -45% | -$5.92M | 3.07% | 3 |
|
|
2018
Q3 | $14.1M | Sell |
149,539
-3,579
| -2% | -$339K | 4.4% | 1 |
|
|
2018
Q2 | $14.2M | Buy |
153,118
+17,160
| +13% | +$1.68M | 4.68% | 1 |
|
|
2018
Q1 | $12.9M | Sell |
135,958
-22,870
| -14% | -$2.51M | 4.7% | 1 |
|
|
2017
Q4 | $15.4M | Sell |
158,828
-4,362
| -3% | -$411K | 5.51% | 1 |
|
|
2017
Q3 | $14.5M | Sell |
163,190
-3,678
| -2% | -$280K | 5.78% | 1 |
|
|
2017
Q2 | $12.1M | Buy |
166,868
+6,198
| +4% | +$417K | 5.13% | 3 |
|
|
2017
Q1 | $10.5M | Buy |
160,670
+19,286
| +14% | +$1.21M | 5.05% | 3 |
|
|
2016
Q4 | $8.85M | Buy |
+141,384
| New | +$8.63M | 4.91% | 3 |
|
Other funds holding ABBV
ECSS
ATO
Royal Fund Management's ABBV Position: Q2 2026 in Review
Royal Fund Management increased its AbbVie (ABBV) stake by 7.6% in Q2 2026, buying an estimated $772K and bringing the position to 50,828 shares worth $12.8M. The position accounts for 1.07% of the portfolio, ranked #20.
Royal Fund Management first reported a position in ABBV in Q4 2016 and has held it in 39 quarters since. The position peaked at $15.4M in Q4 2017. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Royal Fund Management held 50,828 shares of AbbVie worth $12.8M as of Q2 2026.
- Royal Fund Management bought 3,590 AbbVie shares in Q2 2026, an estimated $772K.
- AbbVie made up 1.07% of Royal Fund Management's portfolio in Q2 2026, its #20 holding.
- Royal Fund Management first reported a position in AbbVie in Q4 2016 and has held it in 39 quarters since.
- Royal Fund Management's AbbVie position peaked at $15.4M in Q4 2017.
- 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Royal Fund Management's 13F filing for Q2 2026, filed 20 Jul 2026.